-transparent.png){kind=logo}
A patient with intractable congestive cardiac failure secondary to renovascular hypertension and severe coronary artery disease was infused with the competitive antagonist of angiotensin II, saralasin acetate. The infusion produced an impressive increase in cardiac output and left ventricular stroke work index in parallel with a striking decrease in the systemic and pulmonary vascular resistance, the coronary resistance, and the myocardial oxygen consumption. It is suggested that angiotensin inhibition may present advantages over other forms of treatment of congestive cardiac failure in selected cases.
Related Publications
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
January 1983,
European heart journal,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
November 2002,
Journal of molecular and cellular cardiology,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
January 1978,
Circulation research,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
January 2001,
The Annals of pharmacotherapy,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
March 2005,
Nihon rinsho. Japanese journal of clinical medicine,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
February 1976,
Israel journal of medical sciences,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
October 1978,
British heart journal,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
August 1984,
Drugs,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
January 2011,
Frontiers in physiology,
H Gavras, and
A Flessas, and
T J Ryan, and
H R Brunner, and
D P Faxon, and
I Gavras
January 2006,
Heart failure monitor,
